BHVN Biohaven Corp: Year-over-year net earnings per share growth for the last 12 months
Biohaven Ltd. leverages significant pricing power driven by its unique targeted platforms, while stringent FDA filters and patent protection exclude smaller competitors. Quarterly EPS progress demonstrates profit dynamics, with the value recorded at 48.30. However, global instability and sanctions restrict international logistics and access to innovative therapy.
Biohaven Corp (BHVN) - metric breakdowns and financial figures
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization indicators:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Biohaven Ltd.|BHVN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Biohaven Ltd.|BHVN - Company Debts|Debt to Book Value Biohaven Pharmaceutical|BHVN - Amount of Long-Term Liabilities|Company Short-Term Debts Biohaven|Quick Liquidity Indicator biohavenpharma.com
- earnings and valuation multiples indicators:
BHVN - Net Financial Result|Projected Future Earnings Biohaven Ltd.|BHVN - Price to Earnings Ratio|Forward P/E Multiple Biohaven Pharmaceutical|BHVN - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Biohaven Pharmaceutical|BHVN - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Biohaven|BHVN - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months biohavenpharma.com|BHVN - Earnings per share growth this year|Earnings growth forecast for next year Biohaven Ltd.
Fundamental valuation:Biohaven, BHVN
Capital seeks to decouple resilient assets from speculative instruments through an analysis of real yields. For Biohaven Ltd. (BHVN), which is developing a portfolio of neurological drugs, commercialization dynamics are critical. The quarterly EPS growth rate measures the pace of change in net profit per share, revealing hidden cost increases. This chart allows for an assessment of the business's sensitivity to regulatory risks. The stability of this indicator confirms the company's financial viability.
Competitor analysis for Biohaven Ltd.
BIIB: Quarterly EPS earnings growth|Neurocrine (NBIX) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months RGC|Year-over-year earnings per share growth for the last twelve months AXSM|Quarterly EPS earnings growth ACAD|XENE - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Viking Therapeutics, Inc. VKTX|SUPN: Year-over-year earnings per share growth for the last 12 months|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Corp)|Harmony Biosciences (HRMY) - Year-over-year earnings per share growth for the last twelve months|AMLX (amylyx.com) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months TRVI|PRAX (Praxis Precision Medicines Inc) - Year-over-year earnings per share growth rate for the last twelve months|Quarterly EPS earnings growth AVXL|CeriBell EEG - Year-over-year earnings per share growth for the last 12 months|Prothena Corporation - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Alector Inc. (ALEC)|Annexon - Quarterly EPS earnings growth|OMER: Year-over-year earnings per share growth for the last twelve months|NGNE: Quarterly EPS earnings growth|AC Immune Inc - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VYGR|Year-over-year earnings per share growth for the last twelve months NMRA|Year-over-year earnings per share growth for the last twelve months Scilex (SCLX)|Tevogen Bio Holdings Inc. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Alpha Cognition Inc. ACOG|CGTX: Year-over-year earnings per share growth for the last 12 months|Inhibikase Therapeutics - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months cassavasciences.com|ASRT (assertiotx.com) - Year-over-year net earnings per share growth for the last 12 months|Coya Therapeutics (COYA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months VistaGen Therapeutics, Inc.|OVID: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Acumen Pharmaceuticals (ABOS)|CRVO - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth ATHE (Alterity Therapeutics Limited)|Clene Inc - Year-over-year earnings per share growth for the last twelve months|PepGen Corp - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months annovisbio.com (ANVS)|GRCE (Grace Therapeutics Inc) - Quarterly EPS earnings growth|AIFF: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth KLTO|Quarterly EPS earnings growth neurosense-tx.com (NRSN)|Reviva Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|MetaVia Inc. - Year-over-year earnings per share growth for the last twelve months|NeurAxis - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Helius Medical|passagebio.com (PASG) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months NEUP|Year-over-year net earnings per share growth for the last 12 months NERV|ATHA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Addex Therapeutics Ltd (ADXN)|Year-over-year earnings per share growth for the last twelve months ALZN (alzamend.com)|Cyclerion Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months PTIX (Protagenic Therapeutics Inc.)|Pasithea - Quarterly EPS earnings growth|CRGT (Cortigent, Inc.) - Year-over-year earnings per share growth for the last 12 months|ATXI (Avenue Therapeutics, Inc.) - Year-over-year net earnings per share growth for the last 12 months|BCLI - Year-over-year net earnings per share change for the last twelve months|CARA (Cara Therapeutics, Inc) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months CHRO|Quarterly EPS earnings growth ELYM|ITCI (intracellulartherapies.com) - Year-over-year earnings per one share growth for the last 12 months|Longboard Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Marinus Pharmaceuticals Inc - Year-over-year earnings per share growth for the last twelve months|NKGN - Year-over-year earnings per share growth for the last twelve months|NRBO (NeuroBo Pharma) - Year-over-year earnings per share growth for the last 12 months|Sage Therapeutics, Inc. (SAGE) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months SNPX|TRVN (Trevena) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Vigil Neuro VIGL|Year-over-year net earnings per share growth for the last 12 months WENA (Anew Medical, Inc.)|Quarterly EPS earnings growth Cerevel Corp (CERE)
